Cart
sales@molnova.com
Abemaciclib metabolite M20
CAS No. 2138499-06-4
Abemaciclib metabolite M20( CDK4/6-IN-4 | LSN3106726 )
Catalog No. M26100 CAS No. 2138499-06-4
Abemaciclib metabolite M20 is an active metabolite of Abemaciclib.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 217 | In Stock |
|
| 10MG | 345 | In Stock |
|
| 25MG | 588 | In Stock |
|
| 50MG | 799 | In Stock |
|
| 100MG | 1097 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2204 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAbemaciclib metabolite M20
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib.
-
DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for researches on the treatment of cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsCDK4/6-IN-4 | LSN3106726
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2138499-06-4
-
Formula Weight522.605
-
Molecular FormulaC27H32F2N8O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (9.57 mM)
-
SMILESCCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(CO)n(C(C)C)c4c3)nc2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
-
CDK9-IN-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
-
CDK5 inhibitor 20-22...
CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.
-
BML-259
BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.
